The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Unrestricted antigen recognition by T lymphocytes. This project aims to investigate the unrestricted T cell repertoire; the molecular and structural basis of antigen recognition by unrestricted T cells; and the development of unrestricted T cells. T lymphocytes typically are restricted to detecting foreign molecules (antigens) on the cell membrane in association with specialised antigen-presenting molecules encoded within the highly polymorphic major histocompatibility (MHC) locus (MHC restricti ....Unrestricted antigen recognition by T lymphocytes. This project aims to investigate the unrestricted T cell repertoire; the molecular and structural basis of antigen recognition by unrestricted T cells; and the development of unrestricted T cells. T lymphocytes typically are restricted to detecting foreign molecules (antigens) on the cell membrane in association with specialised antigen-presenting molecules encoded within the highly polymorphic major histocompatibility (MHC) locus (MHC restriction). T lymphocytes that can recognise antigens in the absence of MHC or MHC like molecules challenges a major paradigm in the field of immunology. As T cell based therapy underpins treatments for cancer and infection, new mechanisms of T cell activation that are independent of patient genotype should ultimately create opportunities for therapeutic and commercial development, leading to both health and economic benefits.Read moreRead less
Development of an orally delivered genital herpes vaccine: targeting the reproductive tract using Liporale, a novel lipid-based adjuvant. This project will evaluate the potential of a novel lipid-based adjuvant platform, LiporaleTM, to induce protection against a model sexually transmitted infection, genital herpes, using an orally delivered vaccination approach. Currently 16 per cent of the world's population has been exposed to herpes and there is currently no effective vaccine available.
I am an immunologist determining how the immune system is regulated, with the aim of preventing diseases such as asthma, type 1 diabetes and multiple sclerosis caused by dysregulated immune responses.
New genes and models for inflammatory bowel disease. Inflammatory bowel disease affecting millions of people world-wide and results in a significant economic burden ($100M in Australia per year). In collaboration with Australia’s largest biotechnology company, CSL, we will use a novel approach to discover the causes of inflammatory bowel disease. This work will lead to the development of new animal models of inflammatory bowel disease that are vital for analysing the disease and testing treatmen ....New genes and models for inflammatory bowel disease. Inflammatory bowel disease affecting millions of people world-wide and results in a significant economic burden ($100M in Australia per year). In collaboration with Australia’s largest biotechnology company, CSL, we will use a novel approach to discover the causes of inflammatory bowel disease. This work will lead to the development of new animal models of inflammatory bowel disease that are vital for analysing the disease and testing treatment options. In addition, this work may lead to new approaches to treating this disease. The project will result in a greater understanding of inflammatory bowel disease, the training of highly skilled scientists and potentially lead to economically valuable knowledge.Read moreRead less
Understanding T cell immunity induced by infection. We aim to understand how killer T cells are “programmed” upon activation and acquire their characteristic functions and how these are maintained into immunological memory. This proposal will provide insights important for the design and improvement of vaccine strategies to fight pathogens such as influenza, HIV and even tumors.
Development of purified antibodies that kill virus infected cells. This proposal will develop panels of purified and monoclonal antibodies that kill virus infected cells. These antibodies may show efficacy in preventing HIV infection. This is new technology that could subsequently be harnessed to protect or limit the devastating effects of chronic viruses such as HIV.
Cellular and molecular networks controlling protective immunity. This research aims to understand how a handful of master-regulator genes act to program immune cells required for immune responses to microbes, vaccination and to prevent cancer. It will provide a fundamental advance in our understanding of immune cell development and impact strategies aimed at the prevention and treatment of pathogen infections.
The Role of RNA interference in the induction of immune responses. Our work will allow us to understand a new means by which to alert the immune system to the presence of cancer cells using a new technology called RNA interference. This will hopefully lead to new investment in biotechnology products based on RNA interference, improved treatments for cancers and better health for Australians
I am a clinician-scientist who mainly performs cell biology and biochemistry to understand how cancer is controlled by the immune system and to devise novel immune-based therapies for cancer.